Limited Coverage Drugs – Apixaban for the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE)

Generic Name

Apixaban for deep vein thrombosis (DVT) or pulmonary embolism (PE) treatment

Strength

2.5 mg and 5 mg
Form tablet

Special Authority Criteria

Approval Period

For the treatment of patients with DVT or PE.

Up to 6 months total

 

Practitioner Exemptions

  • None.

Special Notes

  1. The recommended dose of apixaban for the treatment of acute DVT or PE is 10 mg taken orally twice daily for 7 days, followed by 5 mg taken orally twice daily.
  2. PharmaCare coverage of apixaban for the treatment of DVT or PE is an alternative to heparin/warfarin for up to six months. When used for longer than six months, apixaban is more costly than heparin/warfarin. As such, patients with an intended duration of therapy longer than six months should be considered for initiation on heparin/warfarin.
  3. Since renal impairment can increase bleeding risk, it is important to monitor renal function regularly. Other factors that increase bleeding risks should also be assessed and monitored (see product monograph).

Special Authority Request Form(s)